Cao A-Yong, He Min, DI Gen-Hong, Wu Jiong, Lu Jin-Song, Liu Guang-Yu, Shen Zhen-Zhou, Shao Zhi-Ming
Breast Cancer Institute, Cancer Hospital/Cancer Institute, Department of Oncology, Shanghai Medical College, Institutes of Biomedical Science, Fudan University, Shanghai, P.R. China.
Exp Ther Med. 2011 Sep;2(5):917-923. doi: 10.3892/etm.2011.275. Epub 2011 May 26.
Various published studies have been inconclusive in attempting to relate a family history of breast and/or ovarian cancer (BOC) to the survival of breast cancer patients. The aim of the study was to investigate the association of a family history of BOC with tumor characteristics, treatment response and the difference between the prognosis of familial breast cancer (FBC) patients and sporadic breast cancer (SBC) patients. Data on 348 operable FBC patients and 345 SBC patients were retrospectively analyzed. The overall survival (OS) and recurrence/metastasis-free survival (RFS) were compared for both groups. FBC cases were diagnosed at a relatively younger age (51.1±10.4 vs. 53.7±11.0 years, P=0.054) and presented a lower T stage (P=0.000) than the SBC cases. Patients with a family history of BOC had a significantly greater risk of recurrence/metastasis (P= 0.04) and a non-significantly increased risk of death (P=0.06) compared to the SBC patients. In a multivariate analysis, family history of BOC was an independent predictive factor for both recurrence/metastasis rate (P=0.01, HR=0.012, 95% CI 0.02-0.57) and mortality (P=0.044, HR=0.43, 95% CI 0.19-0.98) in the hormone receptor-positive population. Our results found that women diagnosed with FBC had an early onset of disease in the population studied, and the poor outcome of patients with a family history of BOC associated with survival was restricted to the hormone receptor-positive population.
在试图将乳腺癌和/或卵巢癌（BOC）家族史与乳腺癌患者的生存率联系起来方面，各种已发表的研究尚无定论。本研究的目的是调查BOC家族史与肿瘤特征、治疗反应以及家族性乳腺癌（FBC）患者和散发性乳腺癌（SBC）患者预后差异之间的关联。对348例可手术的FBC患者和345例SBC患者的数据进行了回顾性分析。比较了两组的总生存期（OS）和无复发/转移生存期（RFS）。FBC病例的诊断年龄相对较小（51.1±10.4岁对53.7±11.0岁，P=0.054），且T分期低于SBC病例（P=0.000）。与SBC患者相比，有BOC家族史的患者复发/转移风险显著更高（P=0.04），死亡风险虽未显著增加但有所上升（P=0.06）。在多变量分析中，BOC家族史是激素受体阳性人群复发/转移率（P=0.01，HR=0.012，95%CI 0.02 - 0.57）和死亡率（P=0.044，HR=0.43，95%CI 0.19 - 0.98）的独立预测因素。我们的研究结果发现，在所研究的人群中，被诊断为FBC的女性发病较早，且有BOC家族史患者与生存相关的不良预后仅限于激素受体阳性人群。
